- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05440409
Análisis multicéntrico CAR (CAR-MA): estudio retrospectivo para caracterizar los resultados de las células T CAR y las toxicidades relacionadas en niños y adultos jóvenes con B-ALL
Study Description:
This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.
Objectives:
Primary
To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL
Secondary
To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. Completed
To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. Completed
To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
To evaluate the response of extramedullary disease following CAR T-cell therapy.
To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations.
To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.
Study Population and Source of Data: Subjects who were less than < 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL.
Descripción general del estudio
Estado
Descripción detallada
Study Description:
This retrospective protocol focuses on characterizing clinical outcomes and toxicities following CAR T-cell therapy.
Objectives:
Primary
- To evaluate the Response Free Survival (RFS) at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL
Secondary
- To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab and other immunotherapy. COMPLETED.
- To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To evaluate the Complete Response (CR) rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To evaluate the Minimal Residual Disease (MRD) negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. COMPLETED.
- To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes.
- To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T-cell therapy.
- To evaluate the response of extramedullary disease following CAR T-cell therapy.
- To evaluate the frequency of subsequent malignant neoplasms after CAR T-cell therapy.
- To describe response, survival, and toxicities after CAR Tcell therapy in children with trisomy 21 and other important subpopulations.
- To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes.
- To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy.
- To describe response, survival, and toxicities after CAR Tcell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy).
- To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.).
- To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- National Cancer Institute (NCI)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Subjects who were less than or equal to 25 years of age at the time of diagnosis and received a CAR T-cell product for B-ALL. This protocol will be amended to incorporate new research objectives and new data as necessary.
Descripción
- Subjects will not be recruited for this study; however, up to 210 subjects records will be selected from treatment protocols who received CAR therapy for B-ALL. Subject who opted out of the future use of his/her data will be excluded. The subjects enrolled to a CAR T cell therapy treatment protocol within the Pediatric Oncology Branch unless, are < 25 years of age at the time of diagnosis and must have received prior a CAR T-cell product.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: RETROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
1
Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Response free survival (completed)
Periodo de tiempo: 6 months
|
To evaluate the RFS at 6 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab. |
6 months
|
|
Outcome evaluation
Periodo de tiempo: 12 months
|
To retrospectively evaluate outcomes following CAR T-cell therapy across children and young adults with B-ALL |
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Complete Response Rate (completed)
Periodo de tiempo: 12 months
|
To evaluate the CR rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Relapse Rate (completed)
Periodo de tiempo: 12 months
|
To evaluate the incidence of CD19 negative versus CD19 positive relapse following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Response free survival (completed)
Periodo de tiempo: 12 months
|
To evaluate the RFS at 12 months following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Minimal Residual Disease detection (completed)
Periodo de tiempo: 12 months
|
To evaluate the MRD negative remission rate following CD19 CAR stratified by prior blinatumomab vs no prior blinatumomab |
12 months
|
|
Impact of immunotherapies on CAR outcomes
Periodo de tiempo: 12 months
|
To evaluate the impact of prior blinatumomab, prior inotuzumab, and other immunotherapies on subsequent CAR T cell outcomes |
12 months
|
|
Cytopenias after CAR
Periodo de tiempo: 12 months
|
To determine the incidence, severity, resolution and risk factors for early and late cytopenias after CAR T cell outcomes |
12 months
|
|
Response of extramedullary disease
Periodo de tiempo: 12 months
|
To evlauate the response of extramedullary disease following CAR T cell therapy |
12 months
|
|
Frequency of malignant neoplasms
Periodo de tiempo: 12 months
|
To evaluate the response of extramedullary disease following CAR T cell therapy |
12 months
|
|
Response, survival and toxicities in subpopulations
Periodo de tiempo: 12 months
|
To describe response, survival, and toxicities after CAR T-cell therapy in children with trisomy 21 and other important subpopulations. |
12 months
|
|
Impact of next generation sequencing MRD and duration of B cell aplasia
Periodo de tiempo: 12 months
|
To determine the impact of next-generation sequencing MRD results and duration of B-cell aplasia on CAR T cell outcomes. |
12 months
|
|
Frequency of infections
Periodo de tiempo: 12 months
|
To evaluate the frequency of infections and describe immune system function after CAR T-cell therapy. |
12 months
|
|
Response, survival and toxicities after CAR
Periodo de tiempo: 12 months
|
To describe response, survival, and toxicities after CAR T-cell therapy in children with leukemia containing specific cytogenetic lesions (e.gl. TP53, t(1;19), hypodiploidy) |
12 months
|
|
Compare toxicities and outcomes across CAR constructs
Periodo de tiempo: 12 months
|
To compare toxicities and outcomes across CAR T-cell constructs (e.g., different CD19 CAR constructs, dual-targeted CARs, CD22-targeted CARs, etc.) |
12 months
|
|
Impact of CAR on other health-related outcomes
Periodo de tiempo: 12 months
|
To assess the impact of CAR T cells on other health-related outcomes, including, but not limited to, organ function, immune reconstitution, quality of life, and patient-reported outcomes |
12 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sara K Silbert, M.D., National Cancer Institute (NCI)
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Leucemia Linfoide
- Leucemia
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Reaparición
- Leucemia-linfoma linfoblástico de células precursoras
Otros números de identificación del estudio
- 10000651
- 000651-C
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All IPD recorded in the medical record will be shared with intramural investigators upon request.
Marco de tiempo para compartir IPD
Clinical data available during the study and indefinitely.
Criterios de acceso compartido de IPD
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .